Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Трансплантация почки, наличие трансплантированной почки, отмирание и отторжение трансплантата почки

Список литературы

  1. Kramer A., Boenink R., Stel V.S. et al. The ERA-EDTA Registry Annual Report 2018: a summary // Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfaa271
  2. Fresenius medical care annual report 2018. https://www.freseniusmedicalcare.com/fileadmin/data/com/pdf/Media_Center/Publications/Ann ual_Reports/FME_Annual-Report_2018.pdf
  3. Андрусев А.М., Томилина Н.А., Перегудова Н.Г., Шинкарев М.Б. 3аместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества.
  4. http://www.transplant-observatory.org/summary/
  5. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2020; 22(2):8-34. https://doi.org/10.15825/1995-1191-2020-2-8-345
  6. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020. 104, 4S: 1-103.
  7. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11: 2093–2109
  8. Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011; 118 Suppl 1: c209–224.
  9. Thomsen T, Villebro N, Moller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev. 2014: CD002294.
  10. Duerinckx N, Burkhalter H, Engberg SJ, et al. Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients: A Systematic Literature Review and Meta-Analysis. Transplantation. 2016; 100: 2252–2263.
  11. Nourbala MH, Nemati E, Rostami Z, et al. Impact of cigarette smoking on kidney transplant recipients: a systematic review. Iran J Kidney Dis. 2011; 5: 141–148.
  12. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation. 2012; 94: 979–987.
  13. Schold JD, Srinivas TR, Guerra G, et al. A “weight-listing” paradox for candidates of renal transplantation? Am J Transplant. 2007; 7: 550–559.
  14. Molnar MZ, Streja E, Kovesdy CP, et al. Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant. 2011; 11: 725–736.
  15. Gill JS, Lan J, Dong J, et al. The survival benefit of kidney transplantation in obese patients. Am J Transplant. 2013; 13: 2083–2090.
  16. Krishnan N, Higgins R, Short A, et al. Kidney Transplantation Significantly Improves Patient and Graft Survival Irrespective of BMI: A Cohort Study. Am J Transplant. 2015; 15: 2378–2386.
  17. Oberholzer J, Giulianotti P, Danielson KK, et al. Minimally invasive robotic kidney transplantation for obese patients previously denied access to transplantation. Am J Transplant. 2013; 13: 721–728.
  18. Troppmann C, Santhanakrishnan C, Kuo JH, et al. Impact of panniculectomy on transplant candidacy of obese patients with chronic kidney disease declined for kidney transplantation because of a high-risk abdominal panniculus: A pilot study. Surgery. 2016; 159: 1612–1622.
  19. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012; 27: 3816–3822.
  20. Garg L, Chen C, Haines DE. Atrial fibrillation and chronic kidney disease requiring hemodialysis - Does warfarin therapy improve the risks of this lethal combination? Int J Cardiol. 2016; 222: 47–50.
  21. Campbell S, Pilmore H, Gracey D, et al. KHA-CARI guideline: recipient assessment for transplantation. Nephrology (Carlton). 2013; 18: 455–462.
  22. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001; 1 Suppl 2: 3–95
  23. European Renal Best Practice Transplantation Guideline Development G. ERBP Guideline on the Management and Evaluation of the Kidney Donor and Recipient. Nephrol Dial Transplant. 2013; 28 Suppl 2: ii1–71.
  24. Olbrisch ME, Benedict SM, Ashe K, et al. Psychological assessment and care of organ transplant patients. J Consult Clin Psychol. 2002; 70: 771–783.
  25. Dew MA, Switzer GE, DiMartini AF, et al. Psychosocial assessments and outcomes in organ transplantation. Prog Transplant. 2000; 10: 239–259.
  26. Broggi E, Bruyere F, Gaudez F, et al. Risk factors of severe incisional hernia after renal transplantation: a retrospective multicentric casecontrol study on 225 patients. World J Urol. 2017; 35: 1111–1117.

  1. Ooms LS, Verhelst J, Jeekel J, et al. Incidence, risk factors, and treatment of incisional hernia after kidney transplantation: An analysis of 1,564 consecutive patients. Surgery. 2016; 159: 1407–1411
  2. Smith CT, Katz MG, Foley D, et al. Incidence and risk factors of incisional hernia formation following abdominal organ transplantation. Surg Endosc. 2015; 29: 398–404.
  3. NIH National Institute of Diabetes and Digestive and Kidney Diseases.Overweight & Obesity Statistics. (2017). https://www.niddk.nih.gov/health- information/health-statistics/Pages/overweight-obesity-statistics.aspx (Accessed February 28, 2020).
  4. Nylund KM, Meurman JH, Heikkinen AM, et al. Oral health in patients with renal disease: a longitudinal study from predialysis to kidney transplantation. Clin Oral Investig. 2018; 22: 339–347.
  5. Nylund K, Meurman JH, Heikkinen AM, et al. Oral health in predialysis patients with emphasis on periodontal disease. Quintessence Int. 2015; 46: 899–907.
  6. Veisa G, Tasmoc A, Nistor I, et al. The impact of periodontal disease on physical and psychological domains in long-term hemodialysis patients: a cross-sectional study. Int Urol Nephrol. 2017; 49: 1261–1266.
  7. Grossman DC, Curry SJ, Owens DK, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319: 1901–1913.
  8. Wong G, Howard K, Webster AC, et al. Screening for renal cancer in recipients of kidney transplants. Nephrol Dial Transplant. 2011; 26: 1729–1739.
  9. Данович ГМ. Трансплантация почки. М: ГЭОТАР-Медиа; 2013: 848.
  10. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019; 69: 184–210.
  11. Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164:279–296.
  12. Sanders RD, Bottle A, Jameson SS, et al. Independent preoperative predictors of outcomes in orthopedic and vascular surgery: the influence of time interval between an acute coronary syndrome or stroke and the operation. Ann Surg. 2012; 255: 901–907.
  13. Jorgensen ME, Torp-Pedersen C, Gislason GH, et al. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. JAMA. 2014; 312: 269–277.

  1. LeFevre ML, Force USPST. Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161: 356–362.
  2. Rossitter CW, Vigo RB, Gaber AO, et al. Evaluation of Carotid Ultrasonography Screening Among Kidney Transplant Candidates: A Single-Center, Retrospective Study. Transplant Direct. 2017; 3: e135.
  3. Chadban SJ, Staplin ND. Is it time to increase access to transplantation for those with diabetic end-stage kidney disease? Kidney Int. 2014; 86: 464–466.
  4. Keddis MT, El Ters M, Rodrigo E, et al. Enhanced posttransplant management of patients with diabetes improves patient outcomes. Kidney Int. 2014; 86: 610–618.
  5. Boucek P, Saudek F, Pokorna E, et al. Kidney transplantation in type 2 diabetic patients: a comparison with matched non-diabetic subjects. Nephrol Dial Transplant. 2002; 17: 1678–1683.
  6. Yates CJ, Fourlanos S, Hjelmesaeth J, et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant. 2012; 12: 820–828.
  7. Tydén G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2011; 15(5): 502-4.
  8. Hourmant M, Figueres L, Gicquel A, et al. New rules of ABO-compatibility in kidney transplantation. Transfus Clin Biol. 2019; 26(3): 180-183.
  9. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003;75:971–977.
  10. De Clippel D, Baeten M, Torfs A, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014; 54: 3036– 3042.
  11. Shi X, Lv J, Han W, Zhong X, Xie X, Su B, Ding J. What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta- analysis of 23 cohort studies involving 486,608 recipients. BMC Nephrol. 2018 May 18;19(1):116. doi: 10.1186/s12882-018-0908-3. PMID: 29776389; PMCID: PMC5960106..
  12. Filippone EJ, Farber JL. Humoral immune response and allograft function in kidney transplantation. Am J Kidney Dis. 2015;66:337–347.
  13. Tait BD, S sal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19–47.
  14. Shi X, Liu R, Xie X, Lv J, Han W, Zhong X, Ding J. Effect of human leukocyte antigen mismatching on the outcomes of pediatric kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017 Nov 1;32(11):1939-1948. doi: 10.1093/ndt/gfx259.
  15. Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4: 107–120.
  16. Malinis M, Boucher HW. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019. 33(9):e13548. doi: 10.1111/ctr.13548.
  17. Levitsky J, Doucette K, AST Infectious Diseases Community of Practice. Viral hepatitis in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4: 147–168.
  18. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003; 63: 2222–2229.
  19. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline on the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl. 2018;8:91–165.
  20. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2013; 96: 333–360.
  21. van Walraven C, Austin PC, Knoll G. Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. CMAJ. 2010; 182: 666–672.
  22. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, Т.9, выпуск 2, № 4, 2015.
  23. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326-50.
  24. Chen J, Mohler ER, 3rd, Garimella PS, et al. Ankle Brachial Index and Subsequent Cardiovascular Disease Risk in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2016; 5: pii: e003339.
  25. Wu SW, Lin CK, Hung TW, et al. Subclinical peripheral arterial disease in renal transplantation. Am J Med Sci. 2014; 347: 267–270.
  26. Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol. 2005; 16: 808– 816.
  27. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 64: e77–137.
  28. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. 2012; 126: 617–663.
  29. Sarkio S, Halme L, Kyllonen L, et al. Severe gastrointestinal complications after 1,515 adult kidney transplantations. Transpl Int. 2004; 17: 505–510.
  30. Telkes G, Peter A, Tulassay Z, et al. High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation. Nephrol Dial Transplant. 2011; 26: 727–732.
  31. Hajj P, Ferlicot S, Massoud W, et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology, 2009, 74, 631-634.
  32. Boissier R, Hevia V, Bruins H, et al. The risk of tumour recurrence of patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol, 2018, 73, 94-108.
  33. Ильинский И.М., Розенталь Р.Л. Патология почечных аллотрансплантатов.- «Зинатне».- Рига.- 1990.- 175 с.
  34. Трансплантология. Руководство для врачей / Под редакцией академика В.И. Шумакова.- Москва.- Медицинское информационное агентство.- 2006.- 540 с.
  35. Тырин В.В. Пункционная биопсия трансплантированной почки в интерпретации ее дисфункции и выборе тактики лечения / Автореферат диссертации … доктора медицинских наук.- Москва.- 2006.- 50 с.
  36. Suhorukov Vadim. The role of core biopsy in kidney graft pathology diagnostics / Summary of Doctoral Thesis for obtaining a Doctor of Medicine degree Speciality - Transplantation.- Riga.- 2011.- 38 p.
  37. Столяревич Е.С. Хроническая дисфункция трансплантированной почки: морфологическая картина, особенности течения, подходы к профилактике и лечению / Автореферат диссертации … доктора медицинских наук.- Москва.- 2010.- 48 с.
  38. Столяревич Е.С. Хроническая трансплантационная нефропатия: клинико- морфологические сопоставления и факторы прогрессирования / Автореферат диссертации … кандидата медицинских наук.- Москва.- 2002.- 25 с.
  39. Малов И.П. Гистологическое и иммуноморфологическое исследование аллотрансплантированных почек в позднем послеоперационном периоде / Автореферат диссертации … кандидата медицинских наук.- Москва.-2002.- 27 с.
  40. Шумаков В.И., Ильинский И.М., Белецкая Л.В., Малов И.П., Тырин В.В., Зайденов В.А., Томилина Н.А. Гистологическое и иммуноморфологическое исследование хронического отторжения аллотрансплантированных почек // Вестник трансплантологии и искусственных органов.- 2000.-N 3.- С. 30-34.
  41. Шумаков В.И., Малов И.П., Ильинский И.М., Тырин В.В., Белецкая Л.В., Зайденов В.В., Томилина Н.А., Гордюшина В.С. Виды патологии аллотрансплантированных трупных почек в позднем послеоперационном периоде по данным исследования пункционных биоптатов // Вестник трансплантологии и искусственных органов.- 2000.- N 1.- C. 11-14.
  42. Розенталь Р.Л., Ильинский И.М., Тихомирова Т.Е, Берзиня Р.Э. Туберкулез после трансплантации почки // Терапевтический архив, 1980, № 4, с. 128-132.
  43. Ротова И.Д. Гистологическая и иммуногистохимическая диагностика цитомегаловирусной инфекции в пункционных биоптатах аллотрансплантированных почек / Автореферат диссертации … кандидата медицинских наук.- Москва.- 2007.- 23 с.
  44. Trofe-Clark J, Sawinski D. BK and Other Polyomaviruses in Kidney Transplantation.BK and Other Polyomaviruses in Kidney Transplantation.Semin Nephrol. 2016 Sep;36(5):372-385. doi: 10.1016/j.semnephrol.2016.05.014.
  45. Van Loo, A.A., et al. Pretransplantation hemodialysis strategy influences early renal graft function. J Am Soc Nephrol, 1998. 9: 473. https://www.ncbi.nlm.nih.gov/pubmed/9513911
  46. Abramowicz, D., et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant, 2015. 30: 1790. https://www.ncbi.nlm.nih.gov/pubmed/25007790
  47. Task Force for Preoperative Cardiac Risk. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J, 2009. 30: 2769. https://academic.oup.com/eurheartj/article/30/22/2769/478458
  48. Benahmed, A., et al. Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: A case-control study. Nephrol Dial Transplant, 2014. 29: 463. https://www.ncbi.nlm.nih.gov/pubmed/24275542
  49. Osman, Y., et al. Necessity of Routine Postoperative Heparinization in Non-Risky Live-Donor Renal Transplantation: Results of a Prospective Randomized Trial. Urology, 2007. 69: 647. https://www.ncbi.nlm.nih.gov/pubmed/17445644
  50. Orlando, G., et al. One-shot versus multidose perioperative antibiotic prophylaxis after kidney transplantation: a randomized, controlled clinical trial. Surgery, 2015. 157: 104. https://www.ncbi.nlm.nih.gov/pubmed/25304836
  51. Choi, S.U., et al. Clinical significance of prophylactic antibiotics in renal transplantation. Transplant Proc, 2013. 45: 1392. https://www.ncbi.nlm.nih.gov/pubmed/23726580
  52. O’Malley, C.M., et al. A randomized, double-blind comparison of lactated Ringer’s solution and 0.9% NaCl during renal transplantation. Anesth Analg, 2005. 100: 1518. https://www.ncbi.nlm.nih.gov/pubmed/15845718
  53. Othman, M.M., et al. The impact of timing of maximal crystalloid hydration on early graft function during kidney transplantation. Anesth Analg, 2010. 110: 1440. https://www.ncbi.nlm.nih.gov/pubmed/20418304
  54. Dalton, R.S., et al. Physiologic impact of low-dose dopamine on renal function in the early post renal transplant period. Transplantation, 2005. 79: 1561. https://www.ncbi.nlm.nih.gov/pubmed/15940046
  55. Ciapetti, M., et al. Low-dose dopamine in kidney transplantation. Transplant Proc, 2009. 41: 4165. https://www.ncbi.nlm.nih.gov/pubmed/20005360
  56. Chedid, M.F., et al. Living donor kidney transplantation using laparoscopically procured multiple renal artery kidneys and right kidneys. J Am Coll Surg, 2013. 217: 144.
  57. Joseph S. et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for Apheresis: the 7th special issue. Journal of Clinical Apheresis 2016. 31:149-338.
  58. Мойсюк Я.Г., Сушков А.И. Несовместимые по группе крови родственные трансплантации почки: отдаленные результаты. Альманах клинической медицины. 2017;45(7):535-546. https://doi.org/10.18786/2072-0505-2017-45-7-535-546.
  59. Veroux M, Zerbo D, Basile G, et al. Simultaneous Native Nephrectomy and Kidney Transplantation in Patients With Autosomal Dominant Polycystic Kidney Disease. PLoS One. 2016; 11: e0155481.
  60. Chebib FT, Prieto M, Jung Y, et al. Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease. Transplant Direct. 2015; 1: e43.
  61. Ahmad SB, Inouye B, Phelan MS, et al. Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. Transplantation. 2016; 100: 407–415.
  62. Ciudin, A., et al. Transposition of iliac vessels in implantation of right living donor kidneys. Transplant Proc, 2012. 44: 2945. https://www.ncbi.nlm.nih.gov/pubmed/23195003
  63. Phelan, P.J., et al. Left versus right deceased donor renal allograft outcome. Transpl Int, 2009. 22: 1159. https://www.ncbi.nlm.nih.gov/pubmed/19891044
  64. Feng, J.Y., et al. Renal vein lengthening using gonadal vein reduces surgical difficulty in living-donor kidney transplantation. World J Surg, 2012. 36: 468. https://www.ncbi.nlm.nih.gov/pubmed/21882021
  65. Nghiem, D.D. Use of spiral vein graft in living donor renal transplantation. Clin Transplant, 2008. 22: 719. https://www.ncbi.nlm.nih.gov/pubmed/18673376
  66. Matheus, W.E., et al. Kidney transplant anastomosis: internal or external iliac artery? Urol J, 2009. 6: 260. https://www.ncbi.nlm.nih.gov/pubmed/20027554.
  67. El-Sherbiny, M., et al. The use of the inferior epigastric artery for accessory lower polar artery revascularization in live donor renal transplantation. Int Urol Nephrol, 2008. 40: 283. https://www.ncbi.nlm.nih.gov/pubmed/17721826
  68. Firmin, L.C., et al. The use of explanted internal iliac artery grafts in renal transplants with multiple arteries. Transplantation, 2010. 89: 766. https://www.ncbi.nlm.nih.gov/pubmed/20308866
  69. Oertl, A.J., et al. Saphenous vein interposition as a salvage technique for complex vascular situations during renal transplantation. Transplant Proc, 2007. 39: 140. https://www.ncbi.nlm.nih.gov/pubmed/17275492
  70. Alberts, V.P., et al. Ureterovesical anastomotic techniques for kidney transplantation: a systematic review and meta-analysis. Transpl Int, 2014. 27: 593. https://www.ncbi.nlm.nih.gov/pubmed/24606191
  71. Slagt, I.K., et al. A randomized controlled trial comparing intravesical to extravesical ureteroneocystostomy in living donor kidney transplantation recipients. Kidney Int, 2014. 85: 471. https://www.ncbi.nlm.nih.gov/pubmed/24284515
  72. Dadkhah, F., et al. Modified ureteroneocystostomy in kidney transplantation to facilitate endoscopic management of subsequent urological complications. Int Urol Nephrol, 2010. 42: 285. https://www.ncbi.nlm.nih.gov/pubmed/19760513
  73. Timsit, M.O., et al. Should routine pyeloureterostomy be advocated in adult kidney transplantation? A prospective study of 283 recipients. J Urol, 2010. 184: 2043. https://www.ncbi.nlm.nih.gov/pubmed/20850818
  74. Kehinde, E.O., et al. Complications associated with using nonabsorbable sutures for ureteroneocystostomy in renal transplant operations. Transplant Proc, 2000. 32: 1917. https://www.ncbi.nlm.nih.gov/pubmed/11119999
  75. Wilson, C.H., et al. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev, 2013: CD004925. https://www.ncbi.nlm.nih.gov/pubmed/23771708
  76. Tavakoli, A., et al. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol, 2007. 177: 2260. https://www.ncbi.nlm.nih.gov/pubmed/17509336.
  77. Сайдулаев Д.А., Готье С.В. Профилактика и хирургическая коррекция урологических осложнений у реципиентов почки //Трансплантология: итоги и перспективы. Том XI. 2019 год / Под ред. С.В. Готье. – М. – Тверь: ООО «Издательство «Триада», 2020. – С. 104-105; ISBN 978-5-94789-950-4.
  78. Heidari, M., et al. Transplantation of kidneys with duplicated ureters. Scand J Urol Nephrol, 2010. 44: 337. https://www.ncbi.nlm.nih.gov/pubmed/20653492
  79. Alberts, V.P., et al. Duplicated ureters and renal transplantation: a case-control study and review of the literature. Transplant Proc, 2013. 45: 3239. https://www.ncbi.nlm.nih.gov/pubmed/24182792
  80. Roach, J. P., Bock, M. E., & Goebel, J. (2017). Pediatric kidney transplantation. Seminars in Pediatric Surgery, 26(4), 233–240. doi:10.1053/j.sempedsurg.2017.07.006.
  81. Ghane Sharbaf F, Bitzan M, Szymanski KM, et al. Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects. Pediatr Nephrol. 2012; 27: 1179–1188.
  82. Dimitroulis, D., et al. Vascular complications in renal transplantation: a single- center experience in 1367 renal transplantations and review of the literature. Transplant Proc, 2009. 41: 1609. https://www.ncbi.nlm.nih.gov/pubmed/19545690
  83. Pawlicki, J., et al. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation. Transplant Proc, 2011. 43: 3013. https://www.ncbi.nlm.nih.gov/pubmed/21996213
  84. Rouviere, O., et al. Acute thrombosis of renal transplant artery: graft salvage by means of intra-arterial fibrinolysis. Transplantation, 2002. 73: 403. https://www.ncbi.nlm.nih.gov/pubmed/11884937
  85. Domagala, P., et al. Complications of transplantation of kidneys from expanded- criteria donors. Transplant Proc, 2009. 41: 2970. https://www.ncbi.nlm.nih.gov/pubmed/19857652
  86. Giustacchini, P., et al. Renal vein thrombosis after renal transplantation: an important cause of graft loss. Transplant Proc, 2002. 34: 2126. https://www.ncbi.nlm.nih.gov/pubmed/12270338
  87. Wuthrich, R.P. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens, 2001. 10: 409. https://www.ncbi.nlm.nih.gov/pubmed/11342806
  88. Parajuli, S., et al. Hypercoagulability in Kidney Transplant Recipients. Transplantation, 2016. 100: 719. https://www.ncbi.nlm.nih.gov/pubmed/26413991
  89. Granata, A., et al. Renal transplant vascular complications: the role of Doppler ultrasound. J Ultrasound, 2015. 18: 101. https://www.ncbi.nlm.nih.gov/pubmed/26191097
  90. Hogan, J.L., et al. Late-onset renal vein thrombosis: A case report and review of the literature. Int J Surg Case Rep, 2015. 6C: 73. https://www.ncbi.nlm.nih.gov/pubmed/25528029
  91. Hurst, F.P., et al. Incidence, predictors and outcomes of transplant renal artery stenosis after kidney transplantation: analysis of USRDS. Am J Nephrol, 2009. 30: 459. https://www.ncbi.nlm.nih.gov/pubmed/19776559
  92. Willicombe, M., et al. Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. Am J Transplant, 2014. 14: 133. https://www.ncbi.nlm.nih.gov/pubmed/24354873
  93. Ghazanfar, A., et al. Management of transplant renal artery stenosis and its impact on long-term allograft survival: a single-centre experience. Nephrol Dial Transplant, 2011. 26: 336. https://www.ncbi.nlm.nih.gov/pubmed/20601365
  94. Seratnahaei, A., et al. Management of transplant renal artery stenosis. Angiology, 2011. 62: 219. https://www.ncbi.nlm.nih.gov/pubmed/20682611
  95. Atray, N.K., et al. Post transplant lymphocele: a single centre experience. Clin Transplant, 2004. 18 Suppl 12: 46. https://www.ncbi.nlm.nih.gov/pubmed/15217407
  96. Ulrich, F., et al. Symptomatic lymphoceles after kidney transplantation - multivariate analysis of risk factors and outcome after laparoscopic fenestration. Clin Transplant, 2010. 24: 273. https://www.ncbi.nlm.nih.gov/pubmed/19719727
  97. Lucewicz, A., et al. Management of primary symptomatic lymphocele after kidney transplantation: a systematic review. Transplantation, 2011. 92: 663. https://www.ncbi.nlm.nih.gov/pubmed/21849931
  98. Capocasale, E., et al. Octreotide in the treatment of lymphorrhea after renal transplantation: a preliminary experience. Transplant Proc, 2006. 38: 1047. https://www.ncbi.nlm.nih.gov/pubmed/16757259
  99. Kayler, L., et al. Kidney transplant ureteroneocystostomy techniques and complications: review of the literature. Transplant Proc, 2010. 42: 1413. https://www.ncbi.nlm.nih.gov/pubmed/20620446
  100. Secin, F.P., et al. Comparing Taguchi and Lich-Gregoir ureterovesical reimplantation techniques for kidney transplants. J Urol, 2002. 168: 926. https://www.ncbi.nlm.nih.gov/pubmed/12187192
  101. Dinckan, A., et al. Early and late urological complications corrected surgically following renal transplantation. Transpl Int, 2007. 20: 702. https://www.ncbi.nlm.nih.gov/pubmed/17511829
  102. Kumar, A., et al. Evaluation of the urological complications of living related renal transplantation at a single center during the last 10 years: impact of the Double-J* stent. J Urol, 2000. 164: 657. https://www.ncbi.nlm.nih.gov/pubmed/10953120
  103. Mazzucchi, E., et al. Primary reconstruction is a good option in the treatment of urinary fistula after kidney transplantation. Int Braz J Urol, 2006. 32: 398. https://www.ncbi.nlm.nih.gov/pubmed/16953905
  104. Davari, H.R., et al. Urological complications in 980 consecutive patients with renal transplantation. Int J Urol, 2006. 13: 1271. https://www.ncbi.nlm.nih.gov/pubmed/17010003
  105. Sabnis, R.B., et al. The development and current status of minimally invasive surgery to manage urological complications after renal transplantation. Indian J Urol, 2016. 32: 186. https://www.ncbi.nlm.nih.gov/pubmed/27555675
  106. Suttle, T., et al. Comparison of Urologic Complications Between Ureteroneocystostomy and Ureteroureterostomy in Renal Transplant: A Meta-Analysis. Exp Clin Transplant, 2016. 14: 276. https://www.ncbi.nlm.nih.gov/pubmed/26925612
  107. Breda, A., et al. Incidence of ureteral strictures after laparoscopic donor nephrectomy. J Urol, 2006. 176: 1065. https://www.ncbi.nlm.nih.gov/pubmed/16890691
  108. Kaskarelis, I., et al. Ureteral complications in renal transplant recipients successfully treated with interventional radiology. Transplant Proc, 2008. 40: 3170. https://www.ncbi.nlm.nih.gov/pubmed/19010224
  109. He, B. Classification of ureteral stenosis and associated strategy for treatment after kidney transplant / B. He, A. Bremner, Y. Han. – Текст : непосредственный // Experimental and Clinical Transplantation. – 2013. – Vol. 11. – Iss. 2. – P. 122–127. doi: 10.6002/ect.2012.0179.
  110. Kristo, B., et al. Treatment of renal transplant ureterovesical anastomotic strictures using antegrade balloon dilation with or without holmium:YAG laser endoureterotomy. Urology, 2003. 62: 831. https://www.ncbi.nlm.nih.gov/pubmed/14624903
  111. Nie, Z., et al. Comparison of urological complications with primary ureteroureterostomy versus conventional ureteroneocystostomy. Clin Transplant, 2010. 24: 615. https://www.ncbi.nlm.nih.gov/pubmed/19925475
  112. Chaykovska, L., et al. Kidney transplantation into urinary conduits with ureteroureterostomy between transplant and native ureter: single-center experience. Urology, 2009. 73: 380. https://www.ncbi.nlm.nih.gov/pubmed/19022489
  113. Helfand, B.T., et al. Reconstruction of late-onset transplant ureteral stricture disease. BJU Int, 2011. 107: 982. https://www.ncbi.nlm.nih.gov/pubmed/20825404
  114. Bartel G, Schwaiger E, Bohmkig GA. Prevention and treatment of Alloantibody- mediated transplant rejection. Transplant Int 2011;24;28:494-507.
  115. Burton SA, Amir N, Asbury A, Lange A, Hardinger KL. Treatment of antibody- mediated rejection in renal transplant patients: a clinical practice survey. Clin Transplant 2015;29;118-123.
  116. Ruangkanchanasetr P et al. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant. Exp Clin Transplant 2014;12;328-333.
  117. Liu, Y., et al. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplant Proc, 2010. 42: 1667. https://www.ncbi.nlm.nih.gov/pubmed/20620496
  118. Sun, Z.J., et al. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis. Transplant Proc, 2015. 47: 2439. https://www.ncbi.nlm.nih.gov/pubmed/26518947
  119. Webster, A.C., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev, 2010: CD003897. https://www.ncbi.nlm.nih.gov/pubmed/20091551
  120. Bamoulid, J., et al. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. Nephrol Dial Transplant, 2016. https://www.ncbi.nlm.nih.gov/pubmed/27798202
  121. Malvezzi, P., et al. Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol, 2015. 4: 110. https://www.ncbi.nlm.nih.gov/pubmed/26457257
  122. Nashan B. Review of the proliferation inhibitor everolimus. ExpertOpin Investig Drugs, 2002; 11: 1845–1857.
  123. Knight S.R., Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation, 2008; 85: р.1675–1685.
  124. Kyllonen L.E., Salmela K.T.. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplantation, 2006; 81: 1010–1015.
  125. Bamoulid, J., et al. Immunosuppression and Results in Renal Transplantation. Eur UrolSuppl,2016. 15: 415. https://www.sciencedirect.com/science/article/pii/S1569905616300823
  126. Kidney Disease Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 2009. 9 Suppl 3: S1. https://www.ncbi.nlm.nih.gov/pubmed/19845597
  127. Bamoulid, J., et al. The need for minimization strategies: current problems of immunosuppression. Transpl Int, 2015. 28: 891. https://www.ncbi.nlm.nih.gov/pubmed/25752992
  128. Jones-Hughes, T., et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 2016. 20: 1. https://www.ncbi.nlm.nih.gov/pubmed/27578428
  129. Leas, B.F., et al., in Calcineurin Inhibitors for Renal Transplant. 2016: Rockville.
  130. Sawinski, D., et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant, 2016. 16: 2117. https://www.ncbi.nlm.nih.gov/pubmed/26990455.
  131. Webster, A.C., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ, 2005. 331: 810. https://www.ncbi.nlm.nih.gov/pubmed/16157605.
  132. Caillard, S., et al. Advagraf((R)), a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transpl Int, 2016. 29: 860. https://www.ncbi.nlm.nih.gov/pubmed/26373896.
  133. McCormack, P.L. Extended-release tacrolimus: a review of its use in de novo kidney transplantation. Drugs, 2014. 74: 2053. https://www.ncbi.nlm.nih.gov/pubmed/25352392.
  134. Molnar, A.O., et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ, 2015. 350: h3163. https://www.ncbi.nlm.nih.gov/pubmed/26101226.
  135. Staatz, C.E., et al. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid- Organ Transplant Patients. Clin Pharmacokinet, 2015. 54: 993. https://www.ncbi.nlm.nih.gov/pubmed/26038096.
  136. van Gelder, T., et al. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int, 2011. 24: 1135. https://www.ncbi.nlm.nih.gov/pubmed/22032583.
  137. Diekmann, F. Immunosuppressive minimization with mTOR inhibitors and belatacept. Transpl Int, 2015. 28: 921. https://www.ncbi.nlm.nih.gov/pubmed/25959589.
  138. Kamar, N., et al. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. Transpl Int, 2015. 28: 928. https://www.ncbi.nlm.nih.gov/pubmed/25557802.
  139. Snanoudj, R., et al. Immunological risks of minimization strategies. Transpl Int, 2015. 28: 901. https://www.ncbi.nlm.nih.gov/pubmed/25809144.
  140. Budde, K., et al. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf, 2010. 9: 981. https://www.ncbi.nlm.nih.gov/pubmed/20795786.
  141. Cooper, M., et al. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando), 2012. 26: 233. https://www.ncbi.nlm.nih.gov/pubmed/22863029.
  142. Staatz, C.E., et al. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol, 2014. 88: 1351. https://www.ncbi.nlm.nih.gov/pubmed/24792322.
  143. van Gelder, T., et al. Mycophenolate revisited. Transpl Int, 2015. 28: 508. https://www.ncbi.nlm.nih.gov/pubmed/25758949.
  144. Wagner, M., et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev, 2015: CD007746. https://www.ncbi.nlm.nih.gov/pubmed/26633102.
  145. Hirsch, H.H., et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin Microbiol Infect, 2014. 20 Suppl 7:
  146. https://www.ncbi.nlm.nih.gov/pubmed/24476010
  147. Le Meur, Y., et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando), 2011. 25: 58. https://www.ncbi.nlm.nih.gov/pubmed/21454067.
  148. Haller, M.C., et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev, 2016: CD005632. https://www.ncbi.nlm.nih.gov/pubmed/27546100.
  149. Mathis, A.S., et al. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant, 2014. 4: 57. https://www.ncbi.nlm.nih.gov/pubmed/25032096.
  150. Kunz, R., et al. Maintenance therapy with triple versus double immunosuppressive regimen in renal transplantation: a meta-analysis. Transplantation, 1997. 63: 386. https://www.ncbi.nlm.nih.gov/pubmed/9039928.
  151. Halleck, F., et al. An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol, 2012. 8: 1337. https://www.ncbi.nlm.nih.gov/pubmed/22928953.
  152. Ventura-Aguiar, P., et al. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf, 2016. 15: 303. https://www.ncbi.nlm.nih.gov/pubmed/26667069.
  153. Witzke, O., et al. Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? Transplant Rev (Orlando), 2016. 30: 3. https://www.ncbi.nlm.nih.gov/pubmed/26603484.
  154. Xie, X., et al. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol, 2015. 16: 91. https://www.ncbi.nlm.nih.gov/pubmed/26126806.
  155. Shipkova, M., et al. Therapeutic Drug Monitoring of Everolimus: A Consensus Report. Ther Drug Monit, 2016. 38: 143. https://www.ncbi.nlm.nih.gov/pubmed/26982492.
  156. Liefeldt, L., et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant, 2012. 12: 1192. https://www.ncbi.nlm.nih.gov/pubmed/22300538.
  157. Halleck, F., et al. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol, 2012. 8: 687. https://www.ncbi.nlm.nih.gov/pubmed/23026948.
  158. Ponticelli, C., et al. Skin cancer in kidney transplant recipients. J Nephrol, 2014. 27: 385. https://www.ncbi.nlm.nih.gov/pubmed/24809813.
  159. Федеральный закон от 21.11.2011 N 323-ФЗ (ред. от 31.07.2020) "Об основах охраны здоровья граждан в Российской Федерации"
  160. Nicoletto BB, Fonseca NK, Manfro RC, Goncalves LF, Leitao CB, Souza GC. Effects of obesity on kidney transplantation outcomes: a systematic review and meta-analysis. Transplantation 2014;98:167-76.
  161. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014;384:755-65.
  162. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. American journal of kidney diseases : the official journal of the National Kidney Foundation 2003;41:493-6.
  163. Heiwe S, Jacobson SH. Exercise Training in Adults With CKD: A Systematic Review and Meta-analysis. American journal of kidney diseases: the official journal of the National Kidney Foundation 2014;64:383-93.
  164. Machnicki G, Pinsky B, Takemoto S, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009;9:494-505.
  165. Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. Transplantation 2013;96:1015-24.
  166. Pezeshki M, Taherian AA, Gharavy M, Ledger WL. Menstrual characteristics and pregnancy in women after renal transplantation. Int J Gynaecol Obstet 2004;85(2):119–25. http://www.ncbi.nlm.nih.gov/pubmed/15099772.
  167. Bar J, Ben-Rafael Z, Pados A, Orvieto R, Boner G, Hod M. Prediction of pregnancy outcome in subgroups of women with renal disease. Clin Nephrol 2000;53(6):437–44. http://www.ncbi.nlm.nih.gov/pubmed/10879663.
  168. Stratta P, Canavese C, Giacchino F, Mesiano P, Quaglia M, Rossetti M. Pregnancy in kidney transplantation: satisfactory outcomes and harsh realities. J Nephrol 2003;16(6):792-–806. http://www.ncbi.nlm.nih.gov/pubmed/14736006.
  169. Hagay ZJ, Biran G, Ornoy A, Reece EA. Congenital cytomegalovirus infection: along-standing problem still seeking a solution. Am J Obstet Gynecol 1996;174(1 Pt 1):241–5. http://www.ncbi.nlm.nih.gov/pubmed/8572014.
  170. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000;70(12):1718–21. http://www.ncbi.nlm.nih.gov/pubmed/11152103.
  171. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, Warty V, Starzl TE. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997;64(4):559–65. http://www.ncbi.nlm.nih.gov/pubmed/9293865.
  172. Sifontis NM, Coscia LA, Costantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to micophenolate mofetil or sirolimus. Transplantation 2006;82(12):1698–702. http://www.ncbi.nlm.nih.gov/pubmed/17198262.
  173. Davison JM, Milne JEC. Pregnancy and renal transplantation. Br J Urol 1997;80(Suppl 1):29–32. http://www.ncbi.nlm.nih.gov/pubmed/9240221.
  174. Sgro MD, Barozzino T, Mirghani HM, Sermer M, Moscato L, Akoury H, Koren G, Chitayat DA. Pregnancy outcome post renal transplantation. Teratology 2002;65(1):5–9. http://www.ncbi.nlm.nih.gov/pubmed/11835226.
  175. Jardine, A.G., et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet, 2011. 378: 1419.https://www.ncbi.nlm.nih.gov/pubmed/22000138.
  176. Liefeldt, L., et al. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int, 2010. 23: 1191.https://www.ncbi.nlm.nih.gov/pubmed/21059108.
  177. Nankivell, B.J., et al. Diagnosis and prevention of chronic kidney allograft loss. Lancet, 2011. 378: 1428.https://www.ncbi.nlm.nih.gov/pubmed/22000139.
  178. Boor, P., et al. Renal allograft fibrosis: biology and therapeutic targets. Am J Transplant, 2015. 15: 863. https://www.ncbi.nlm.nih.gov/pubmed/25691290.
  179. Westall, G.P., et al. Antibody-mediated rejection. Curr Opin Organ Transplant, 2015. 20: 492. https://www.ncbi.nlm.nih.gov/pubmed/26262460.
  180. Chapman, J.R. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant, 2011. 11: 693.https://www.ncbi.nlm.nih.gov/pubmed/21446974.
  181. Higgins, R.M., et al. Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant, 2015. 30: 1972.https://www.ncbi.nlm.nih.gov/pubmed/25500804.
  182. Wongsaroj, P., et al. Modern approaches to incompatible kidney transplantation. World J Nephrol, 2015. 4: 354.https://www.ncbi.nlm.nih.gov/pubmed/26167458.
  183. Naesens, M. Zero-Time Renal Transplant Biopsies: A Comprehensive Review. Transplantation, 2016. 100: 1425.https://www.ncbi.nlm.nih.gov/pubmed/26599490.
  184. Kasiske, B.L., et al. The role of procurement biopsies in acceptance decisions for kidneys retrieved for transplant. Clin J Am Soc Nephrol, 2014. 9: 562.https://www.ncbi.nlm.nih.gov/pubmed/24558053.
  185. Трансплантология. Фармакотерапия без ошибок // руководство для врачей / под ред. С. В. Готье и Я. Г. Мойсюка. — М.: Е-ното, 2014. — 432 с.
  186. Douketis, J.D., et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141. https://pubmed.ncbi.nlm.nih.gov/22315266
  187. Pawlicki, J., et al. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation. Transplant Proc, 2011. 43: 3013. https://pubmed.ncbi.nlm.nih.gov/
  188. Rouviere, O., et al. Acute thrombosis of renal transplant artery: graft salvage by means of intraarterial fibrinolysis. Transplantation, 2002. 73: 403.
  189. Bohmig, G.A., et al. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol, 2015. 11: 732.
  190. Dalton, R.S., et al. Physiologic impact of low-dose dopamine on renal function in the early post renal transplant period. Transplantation, 2005. 79: 1561. https://pubmed.ncbi.nlm.nih.gov/15940046
  191. Ciapetti, M., et al. Low-dose dopamine in kidney transplantation. Transplant Proc, 2009. 41: 4165. https://pubmed.ncbi.nlm.nih.gov/20005360
  192. Hanif, F., et al. Outcome of renal transplantation with and without intra-operative diuretics. Int J Surg, 2011. 9: 460
  193. Биктимиров, Т. Р. Оперативное лечение аутосомно-доминантного поликистоза почек / Т. Р. Биктимиров, А. Г. Мартов, Р. Г. Биктимиров, А. В. Баранов, И. А. Милосердов, А. А. Капутовский, А. М. Хитрых // Урология. – 2021. – № 4. – С. 121– 125. DOI: 10.18565/urology.2021.4.121-125
  194. Boissier, R., et al. Benefits and harms of benign prostatic obstruction treatments in renal transplanted patients. PROSPERO, 2019. CRD42019136477.
  195. Boissier, R., et al. Effectiveness of interventions on nephrolithiasis in transplanted kidney. PROSPERO, 2019. CRD42019136474.
  196. Webster, A.C., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev, 2010: CD003897. https://pubmed.ncbi.nlm.nih.gov/20091551 RENAL TRANSPLANTATION - TEXT UPDATE 2021 53
  197. Lim, W., et al. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transplant Int, 2010. 23: 1207. https://pubmed.ncbi.nlm.nih.gov/20536789
  198. McKeage, K., et al. Basiliximab: A review of its use as induction therapy in renal transplantation. BioDrugs, 2010. 24: 55. https://pubmed.ncbi.nlm.nih.gov/20055533
  199. Hellemans, R., et al. Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? Am J Transplant, 2017. 17: 22. https://pubmed.ncbi.nlm.nih.gov/27223882
  200. Jones-Hughes, T., et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 2016. 20: 1. https://pubmed.ncbi.nlm.nih.gov/27578428 239. Leas, B.F., et al., Calcineurin Inhibitors for Renal Transplant. 2016: Rockville (MD): AHRQ. https://www.ncbi.nlm.nih.gov/books/NBK356377
  201. Sawinski, D., et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant, 2016. 16: 2117.
  202. Ekberg, H., et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation, 2011. 92: 82. https://pubmed.ncbi.nlm.nih.gov/21562449
  203. Xia, T., et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: A systematic review and meta-analysis. Drug Des Devel Ther, 2018. 12: 417. https://pubmed.ncbi.nlm.nih.gov/29535503
  204. Gallagher, M., et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 2009. 87: 1877. https://pubmed.ncbi.nlm.nih.gov/19543068
  205. Liu, J.Y., et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: A meta-analysis and economics evaluation. Am J Ther, 2016. 23: e810. https://pubmed.ncbi.nlm.nih.gov/25299636
  206. Opelz, G., et al. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation, 2009. 87: 795. https://pubmed.ncbi.nlm.nih.gov/19300179
  207. Hill, P., et al. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database of Syst Rev, 2017. 2017: CD004759. https://pubmed.ncbi.nlm.nih.gov/28073178
  208. Webster, A.C., et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database of Syst Rev, 2017. 2017: CD004756. https://pubmed.ncbi.nlm.nih.gov/28731207
  209. Gill, J., et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clinical Journal of the Am Soc Nephrol, 2011. 6: 1168. https://pubmed.ncbi.nlm.nih.gov/21511836
  210. Deshpande NA, James NT, Kucirka LM. et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant 2011; 11: 2388– 2404 - PubMed
  211. Bramham K, Nelson-Piercy C, Gao H. et al. Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol 2013; 8: 290–298 - PMC -PubMed
  212. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 (Suppl 4): 50–55 - PubMed
  213. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk.Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, Calamia JC, Thummel KE, Shen DD, Davis CL, Hebert MF.Br J Clin Pharmacol. 2013 Dec;76(6):988-96. doi: 10.1111/bcp.12122.PMID: 23528073
  214. Jones-Hughes, T., et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 2016. 20: 1. https://pubmed.ncbi.nlm.nih.gov/27578428
  215. Leas, B.F., et al., Calcineurin Inhibitors for Renal Transplant. 2016: Rockville (MD): AHRQ. https://www.ncbi.nlm.nih.gov/books/NBK356377
  216. Sawinski, D., et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant, 2016. 16: 2117
  217. Sautenet, B., et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double- blind Randomized Placebo controlled Trial. Transplantation, 2016. 100: 391. https://pubmed.ncbi.nlm.nih.gov/26555944
  218. Burton, S.A., et al. Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey. Clin Transplant, 2015. 29: 118. https://pubmed.ncbi.nlm.nih.gov/25430052
  219. Shiferaw WS, Akalu TY, Aynalem YA. Risk Factors for Anemia in Patients with Chronic Renal Failure: A Systematic Review and Meta-Analysis. Ethiop J Health Sci. 2020 Sep;30(5):829-842. doi: 10.4314/ejhs.v30i5.23. PMID: 33911845; PMCID: PMC8047269.
  220. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015 Oct;102(11):1314-24. doi: 10.1002/bjs.9861. PMID: 26349842.
  221. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1087-F1108. doi: 10.1152/ajprenal.00340.2016. Epub 2016 Oct 5. PMID: 27707707.
  222. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011 Oct;6(10):2364-73. doi: 10.2215/CJN.02180311. Epub 2011 Aug 18. PMID: 21852664; PMCID: PMC3186450.
  223. Chang CY, Chien YJ, Kao MC, Lin HY, Chen YL, Wu MY. Pre-operative proteinuria, postoperative acute kidney injury and mortality: A systematic review and meta- analysis. Eur J Anaesthesiol. 2021 Jul 1;38(7):702-714. doi: 10.1097/EJA.0000000000001542
  224. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015 Feb 24;313(8):837-46. doi: 10.1001/jama.2015.0602. PMID: 25710660; PMCID: PMC4410363.
  225. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:937398. doi: 10.1155/2014/937398. Epub 2014 May 15. PMID: 24959595; PMCID: PMC4052068.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*